AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2866135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 30585803 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 100
Study 30585803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 100
Study 29509024 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign® cleaning crystals
Number of subjects: 70
Study 29509024 — intervention group
Group type: EXPERIMENTAL
Intervention: Polident®
Number of subjects: 70
Study 29509024 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine®
Number of subjects: 70
Study 29509024 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% sodium hypochlorite
Number of subjects: 70
Study 29509024 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% vinegar
Number of subjects: 70
Study 29509024 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Number of subjects: 70
Study 29509024 — intervention group
Group type: EXPERIMENTAL
Intervention: Other four cleaning methods
Number of subjects: 70
Study 25394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day) plus aspirin (100 mg/day)
Number of subjects: 0
Study 25394855 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 0
Study 25131413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral care protocol (twice a day including tooth brushing, tongue brushing, flossing, mouth rinse, and lip care)
Number of subjects: 51
Study 25131413 — intervention group
Group type: COMPARATOR
Intervention: Usual oral care practices
Number of subjects: 51
Study 25131413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral care protocol
Number of subjects: 51
Study 22321916 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-administered cognitive behavioural therapy (ICBT), tailored according to symptom profile.
Number of subjects: 128
Study 22321916 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 128
Study 18593759 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus infliximab
Number of subjects: 1049
Study 18593759 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate plus placebo
Number of subjects: 1049
Study 18593759 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 1049
Study 17324246 — intervention group
Group type: EXPERIMENTAL
Intervention: NS2330 (tesofensine)
Number of subjects: 320
Study 17324246 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 (major metabolite of NS2330)
Number of subjects: 320
Study 17324246 — intervention group
Group type: EXPERIMENTAL
Intervention: NS2330
Number of subjects: 320
Study 17324246 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analysis
Number of subjects: 320
Study 15350881 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorway driving
Number of subjects: 0
Study 15350881 — intervention group
Group type: COMPARATOR
Intervention: Conventional road driving
Number of subjects: 0
Study 11453961 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa + GH
Number of subjects: 30
Study 11453961 — intervention group
Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 30
Study 7687717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg daily)
Number of subjects: 14
Study 7687717 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (20 mg daily)
Number of subjects: 14
Study 3771812 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg tid)
Number of subjects: 16
Study 3771812 — intervention group
Group type: COMPARATOR
Intervention: Triazolam alone
Number of subjects: 16
Study 29288507 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function training
Number of subjects: 62
Study 29288507 — intervention group
Group type: COMPARATOR
Intervention: Active control group (passive information activities)
Number of subjects: 62
Study 27497110 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 827
Study 27497110 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study 25638697 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-task group
Number of subjects: 0
Study 25638697 — intervention group
Group type: COMPARATOR
Intervention: Whole-task group
Number of subjects: 0
Study 24217262 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ventilation (5 ml/kg tidal volume, 5/min frequency, zero end-expiratory pressure)
Number of subjects: 59
Study 21396775 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 16
Study 21396775 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib + Remifentanil
Number of subjects: 16
Study 21396775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac + Remifentanil
Number of subjects: 16
Study 21396775 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 16
Study 21396775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 16
Study 18490588 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-potency corticosteroid 30 minutes before UV-B exposure
Number of subjects: 20
Study 18490588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency corticosteroid 30 minutes before UV-B exposure
Number of subjects: 20
Study 18490588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency corticosteroid 6 hours after UV-B exposure
Number of subjects: 20
Study 18490588 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-potency corticosteroid 6 hours after UV-B exposure
Number of subjects: 20
Study 18490588 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-potency corticosteroid 23 hours after UV-B exposure
Number of subjects: 20
Study 18490588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency corticosteroid 23 hours after UV-B exposure
Number of subjects: 20
Study 18490588 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 20
Study 16525677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphokine-activated killer (LAK) cell therapy
Number of subjects: 15
Study 16525677 — intervention group
Group type: COMPARATOR
Intervention: Control group (open cholecystectomy)
Number of subjects: 15
Study 16525677 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagectomy without LAK cell therapy
Number of subjects: 15
Study 14503834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye extraction method (dissolution in 65% nitric acid)
Number of subjects: 40
Study 14503834 — intervention group
Group type: COMPARATOR
Intervention: Fluid filtration method
Number of subjects: 40
Study 14503834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye penetration method (2% methylene blue)
Number of subjects: 40
Study 11118174 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial blockade (epidural or spinal anaesthesia)
Number of subjects: 9559
Study 9107083 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of recombinant human erythropoietin (rhEpo) 500 U/kg/day for 30 days after transplant
Number of subjects: 20
Study 9107083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1347258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol (oral, once a day for 2 weeks)
Number of subjects: 25
Study 1347258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3799768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 60
Study 3799768 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 60
Study 3799768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (vaginal delivery and cesarean section)
Number of subjects: 60
Study 31392840 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tregopil administered 10 to 20 minutes before a meal
Number of subjects: 0
Study 31392840 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tregopil with a 6-hour between-meal interval
Number of subjects: 0
Study 31392840 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tregopil 4-hour group during afternoon meal
Number of subjects: 0
Study 31392840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber meal
Number of subjects: 0
Study 31392840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0
Study 31392840 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour between-meal interval
Number of subjects: 0
Study 31392840 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tregopil
Number of subjects: 0
Study 30111284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with dexmedetomidine
Number of subjects: 114
Study 30111284 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (control group)
Number of subjects: 114
Study 26636246 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline effusion-synovitis maximal area
Number of subjects: 406
Study 26636246 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment of effusion-synovitis
Number of subjects: 406
Study 26636246 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline structural measures
Number of subjects: 406
Study 25903783 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of adequate antimicrobial treatment
Number of subjects: 0
Study 25903783 — intervention group
Group type: COMPARATOR
Intervention: 14 days of adequate antimicrobial treatment
Number of subjects: 0
Study 23078110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 22
Study 23078110 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 22
Study 22142314 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (PDS Plus)
Number of subjects: 485
Study 22142314 — intervention group
Group type: COMPARATOR
Intervention: Uncoated sutures (PDS II)
Number of subjects: 485
Study 22142314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Triclosan-coated and Uncoated)
Number of subjects: 485
Study 19819563 — intervention group
Group type: EXPERIMENTAL
Intervention: M&T
Number of subjects: 98
Study 19819563 — intervention group
Group type: EXPERIMENTAL
Intervention: A-M&T
Number of subjects: 98
Study 19819563 — intervention group
Group type: EXPERIMENTAL
Intervention: A-M
Number of subjects: 98
Study 16723783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide 50 mg t.i.d. for 2 weeks
Number of subjects: 108
Study 16723783 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 108
Study 14982550 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated tailored advice letters
Number of subjects: 1058
Study 14982550 — intervention group
Group type: COMPARATOR
Intervention: Standard printed self-help materials (Control)
Number of subjects: 1058
Study 11738225 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (measuring pulse, BP, weight, video consultations)
Number of subjects: 24
Study 11738225 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 24
Study 11738225 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consulting
Number of subjects: 24
Study 11738225 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitored group
Number of subjects: 24
Study 9268188 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin
Number of subjects: 15
Study 9268188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 15
Study 9268188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 15
Study 9268188 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study 8324212 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg + INH 300 mg
Number of subjects: 16
Study 8324212 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin 450 mg + INH 300 mg + pyrazinamide 1500 mg
Number of subjects: 16
Study 3518459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine-tinidazole
Number of subjects: 199
Study 3518459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 199
Study 3518459 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (Control)
Number of subjects: 199
Study 30326632 — intervention group
Group type: EXPERIMENTAL
Intervention: Foxtail millet (50 g/day) for 12 weeks
Number of subjects: 50
Study 27638495 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, provision of splints, and a home exercise programme
Number of subjects: 128
Study 27638495 — intervention group
Group type: COMPARATOR
Intervention: Standard care (continuing on the waitlist without hand therapy intervention)
Number of subjects: 128
Study 24068456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist treatment for 6 months
Number of subjects: 35
Study 24068456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist treatment
Number of subjects: 35
Study 23755954 — intervention group
Group type: COMPARATOR
Intervention: No bed rest (NR)
Number of subjects: 240
Study 23755954 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest (R)
Number of subjects: 240
Study 19864294 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 27
Study 19864294 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 27
Study 18802782 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFiL program (training workshop, communication-network program, consultation service)
Number of subjects: 90
Study 18802782 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 15813400 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback distortion in robotic rehabilitation environment
Number of subjects: 3
Study 12743224 — intervention group
Group type: EXPERIMENTAL
Intervention: ATECO MRV
Number of subjects: 29
Study 12743224 — intervention group
Group type: COMPARATOR
Intervention: Control group (59 patients without IIH)
Number of subjects: 29
Study 10588299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin and mineral supplements for AMD
Number of subjects: 0
Study 10588299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin supplements for cataract
Number of subjects: 0
Study 8912734 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 microg/d for 7 days
Number of subjects: 7
Study 8912734 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 7
Study 1713753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) therapy (8 units daily for 3 days)
Number of subjects: 72
Study 1713753 — intervention group
Group type: COMPARATOR
Intervention: Colloid control (similar volume as FFP)
Number of subjects: 72
Study 6347109 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (10 mg) administered intravenously
Number of subjects: 22
Study 6347109 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously
Number of subjects: 22
Study 31409388 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab in addition to csDMARDs
Number of subjects: 44
Study 31409388 — intervention group
Group type: COMPARATOR
Intervention: Conventional synthetic DMARDs (csDMARDs) alone
Number of subjects: 44
Study 26838353 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate therapist self-disclosure
Number of subjects: 86
Study 26838353 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immediate therapist self-disclosure
Number of subjects: 86
Study 26838353 — intervention group
Group type: COMPARATOR
Intervention: No self-disclosure (control)
Number of subjects: 86
Study 26663632 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI (paroxetine or citalopram)
Number of subjects: 58
Study 26663632 — intervention group
Group type: COMPARATOR
Intervention: Continued CBT
Number of subjects: 58
Study 25149430 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 0
Study 22572022 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 20 min) during 30 min of conventional swallowing training for 10 days
Number of subjects: 16
Study 22572022 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (1 mA for 30 s) during 30 min of conventional swallowing training for 10 days
Number of subjects: 16
Study 19247842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of IPP and VPP peptides
Number of subjects: 166
Study 19247842 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of IPP and VPP peptides
Number of subjects: 166
Study 19247842 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of IPP and VPP peptides
Number of subjects: 166
Study 19247842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 17120252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia (t = 33 degrees C)
Number of subjects: 1001
Study 17120252 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 degrees C)
Number of subjects: 1001
Study 15657667 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity stool substitute
Number of subjects: 10
Study 15657667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity oil with placebo
Number of subjects: 10
Study 15657667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil with orlistat
Number of subjects: 10
Study 15657667 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool substitute with free fatty acid
Number of subjects: 10
Study 15657667 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity enemas
Number of subjects: 10
Study 15657667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity enemas
Number of subjects: 10
Study 11706093 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-interferon-1a (betaINF1a) administered IM once a week at a dose of 30 microg for 24 weeks
Number of subjects: 30
Study 11706093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9202923 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF-RB
Number of subjects: 100
Study 9202923 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS-RB
Number of subjects: 100
Study 9202923 — intervention group
Group type: COMPARATOR
Intervention: TOF-control
Number of subjects: 100
Study 9202923 — intervention group
Group type: COMPARATOR
Intervention: DBS-control
Number of subjects: 100
Study 7619105 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Ca/d as calcium carbonate
Number of subjects: 162
Study 7619105 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 162
Study 7619105 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 162
Study 2908803 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of ketazolam daily for 15 days
Number of subjects: 63
Study 2908803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2908803 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of ketazolam continued for a further 15 days for responders
Number of subjects: 63
Study 2908803 — intervention group
Group type: COMPARATOR
Intervention: Placebo continued for a further 15 days for non-responders
Number of subjects: 63
Study 31996189 — intervention group
Group type: EXPERIMENTAL
Intervention: Social franchise CBCT with community members as counsellors
Number of subjects: 100
Study 31996189 — intervention group
Group type: COMPARATOR
Intervention: Full-time employed HIV counsellors conducting CBCT
Number of subjects: 100
Study 31996189 — intervention group
Group type: EXPERIMENTAL
Intervention: Social franchise CBCT
Number of subjects: 100
Study 31996189 — intervention group
Group type: COMPARATOR
Intervention: Full-time employed HIV counsellors
Number of subjects: 100
Study 30900575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (1.25 g for 5 days)
Number of subjects: 115
Study 30900575 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline (4 g for 30 days)
Number of subjects: 115
Study 28738862 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (rIPC) - induced by inflating a blood pressure cuff placed on the upper arm three times for 5 minutes at 200 mmHg after induction of anesthesia.
Number of subjects: 60
Study 28738862 — intervention group
Group type: COMPARATOR
Intervention: Control group - no preconditioning performed.
Number of subjects: 60
Study 28738862 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (rIPC)
Number of subjects: 60
Study 28738862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25097137 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-Based Iterative Reconstruction (MBIR)
Number of subjects: 100
Study 25097137 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Statistical Iterative Reconstruction (ASiR)
Number of subjects: 100
Study 22865266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 737
Study 21985258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group therapy (CGT)
Number of subjects: 0
Study 21985258 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused psychodynamic group therapy (FGT)
Number of subjects: 0
Study 21985258 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 17674003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25-mm prospective scan
Number of subjects: 100
Study 17674003 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mm prospective scan
Number of subjects: 100
Study 17674003 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mm overlapping retrospective scans
Number of subjects: 100
Study 15310353 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 15310353 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 11779591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 12.5 mg/d for 6 months
Number of subjects: 90
Study 11779591 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (ethinyl estradiol 0.02 mg and desogestrel 0.15 mg) for 6 months
Number of subjects: 90
Study 9521247 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK, 1.5 million IU I.V.)
Number of subjects: 37
Study 9521247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37